Kathy Albain, MD
Hematology & Oncology · Maywood, ILNPI 1679550842
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $97 of the $109 with a category attached, or 89.1%. 4 manufacturers reported payments, led by Novartis at 45.7% of the total. That places this record below the midpoint for hematology & oncology clinicians in IL, where the typical reported total is $2,365.
Across 4 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$50
- Lilly USA, LLC$29
- Terumo Medical Corporation$18
- Gilead$12
Across 75 payments — averaging $9209.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$166K
- Daiichi Sankyo Inc.$142K
- Seagen Inc.$123K
- Pfizer$73K
- AstraZeneca$69K
- Astrazeneca UK Limited$29K
- plus $89K from 6 others
What the payments were for
- Food & beverage$9789%
- Education$1211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $50 |
| Lilly USA, LLC | 1 | $29 |
| Terumo Medical Corporation | 1 | $18 |
| Gilead | 1 | $12 |
How this compares
$109 in reported general payments places this provider in the 10th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 13 | $224,428 |
| IbrancePalbociclib | 11 | $179,319 |
| Exemestane | 59 | $11,622 |
| Erlotinib Hcl | 13 | $3,101 |
| Letrozole | 80 | $1,385 |
| Anastrozole | 51 | $542 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $275 |
| Prochlorperazine Maleate | 16 | $153 |
| Ondansetron Hcl | 12 | $74 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Maywood
- Mohamad Khair KhasawnehMaywood$998K
- Patrick HagenMaywood$141K
- Agne PanerMaywood$75K
- Scott SmithMaywood$55K
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- John BerryBerwyn$687K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.